Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· April 17, 2026

Catalyst Watch: Tesla talks AI5 chips, Intel reports, and the Warner Bros. deal goes to a vote

View original at seekingalpha.com
Catalyst Watch: Tesla talks AI5 chips, Intel reports, and the Warner Bros. deal goes to a vote [Stock Exchange] ShinjiPhotographer Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Betting around the NFL draft has exploded in just the last two years for DraftKings, FanDuel, and BetMGM

    60% confidence

  • Howmet Aerospace is the stock with the tightest trading correlation to GE on earnings day

    60% confidence

  • Options trading implies a double-digit swing for ServiceNow after it reports

    60% confidence

  • Options trading implies a double-digit swing for Equifax after it reports

    60% confidence

  • Options trading implies a 9% share price move for Intel after the earnings release

    60% confidence

  • Analysts think the Adobe Summit will serve as a window into how the company is positioning its platform against broader AI adoption trends

    60% confidence

  • Options trading implies a double-digit swing for Appfolio and Mobileye Global after they report

    60% confidence

  • U.S.–Iran nuclear deal odds climb fast as July odds approach 70%

    60% confidence

  • Short interest is elevated on Lucid Group and C3.ai again

    60% confidence

  • Options trading implies a 7% share price move for GE Aerospace after the earnings release

    60% confidence

  • Options trading implies a 6% share price move for Tesla after the earnings report drops

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com